Day: December 18, 2023

Mithra Receives Positive DSMB Opinion on DONESTA® European Phase 3 Trial

Written by Customer Service on . Posted in Public Companies.

Mithra Receives Positive DSMB Opinion on DONESTA® European Phase 3 Trial The DSMB recommends continuing the phase 3 trial in Europe following regular safety assessment The menopause phase 3 program has previously reported positive top-line data; extension to Europe trial ongoing Additional endometrial data analyses ongoing for inclusion in regulatory submissions Mithra plans to submit DONESTA® for approval by U.S. and European regulators in Q4 2024 Liege, Belgium, 18 December 2023 – 7:00 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces it has received a positive review from the independent Data and Safety Monitoring Board (DSMB) on its phase 3 program for DONESTA®, its investigational, next generation hormone therapy medicine containing estetrol (E4) for the treatment of the symptoms of...

Continue reading

WISeKey’s Subsidiary, WISe.ART, in Collaboration with GMA, Unveils Innovative Digital Renaissance Initiative in Rome

Written by Customer Service on . Posted in Public Companies.

WISeKey’s Subsidiary, WISe.ART, in Collaboration with GMA, Unveils Innovative Digital Renaissance Initiative in Rome GENEVA/Madrid/Rome – December 18, 2023 – WISeKey International Holding Ltd. (“WISeKey”) (SIX: WIHN, NASDAQ: WKEY), a global leader in cybersecurity, digital identity, and Internet of Things (IoT) solutions operating as a holding company, through its subsidiary WISe.ART, a leader in the field of digital art and luxury collectibles, together with GMA, proudly announce the launch of the Digital Renaissance initiative in Rome. This cutting-edge project represents a transformative leap in the promotion, investment, and preservation of art. WISe.ART and GMA’s Digital Renaissance initiative kicks off with the celebrated work of Pedro Sandoval, an artist renowned for his unique blend of contemporary and classical...

Continue reading

Santhera’s AGAMREE® (Vamorolone) Approved in the European Union for the Treatment of Duchenne Muscular Dystrophy

Written by Customer Service on . Posted in Public Companies.

European Commission (EC) grants marketing authorization for AGAMREE® for the treatment of Duchenne muscular dystrophy (DMD) in patients aged 4 years and older AGAMREE® is the only approved medication in the European Union (EU) for treating DMD, and the first DMD treatment approved in both the U.S. and EU First commercial launch of AGAMREE®, in Germany, expected in Q1-2024 EMA acknowledges safety benefits of AGAMREE® with regards to preserving bone health and maintaining growth compared to standard of care corticosteroids Pratteln, Switzerland, December 18, 2023 – Santhera Pharmaceuticals (SIX: SANN) announces that AGAMREE® (vamorolone) has been approved in the European Union (EU) for the treatment of Duchenne muscular dystrophy (DMD) in patients 4 years of age and older, independent of the underlying mutation and ambulatory status....

Continue reading

Mezcal Market Size to Hit USD 2,065.04 Million by 2030 | Exclusive Report by Fortune Business Insights™

Written by Customer Service on . Posted in Mergers And Acquisitions.

Companies covered in mezcal market are Ilegal Mezcal (U.S.), Mezcal Vago (Mexico), Rey Campero (Mexico), Wahaka Mezcal (Mexico), Casa Cortés (Mexico), Xiaman Spirits GmbH (Austria), Diageo Plc. (U.K.), Pernod Ricard (France), Mezcal Amarás (Mexico), SU Casa Mezcal (U.S.) and more players profiled. Mezcal Market Mezcal Market Size Pune, india, Dec. 18, 2023 (GLOBE NEWSWIRE) — The global mezcal market size was valued at USD 922.02 million in 2022 and is expected to be worth USD 1,016.43 million in 2023. The market is projected to reach USD 2,065.04 million by 2030, recording a CAGR of 10.66% during the forecast period. Mezcal is a traditional Mexican distilled drink made from the fermented juices of cooked agave plants. The spirit is made from many varieties of agave, except blue agave, and is majorly produced in Oaxaca,...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.